Zacks Research Has Bullish Forecast for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Research analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for Becton, Dickinson and Company in a report issued on Tuesday, January 21st. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $4.02 per share for the quarter, up from their prior estimate of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.42 EPS.

Several other research analysts also recently weighed in on the company. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $243.69 on Thursday. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $248.42. The stock has a 50-day moving average of $227.70 and a 200 day moving average of $232.88. The stock has a market capitalization of $70.67 billion, a price-to-earnings ratio of 41.02, a PEG ratio of 1.72 and a beta of 0.39.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.71%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,844 shares of company stock worth $2,210,716. Insiders own 0.36% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. State Street Corp lifted its holdings in shares of Becton, Dickinson and Company by 0.8% in the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after acquiring an additional 106,616 shares during the last quarter. Geode Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after buying an additional 460,440 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Becton, Dickinson and Company by 6.4% during the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after buying an additional 302,893 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.